KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions.

Peter Malfertheiner, Eve Versage, Esther Van Twuijver, Giuliano Rizzardini, Matthew Hohenboken

Vaccines (Basel) 13(4) 379

PMID40333232
PMCIDPMC12030940
DOI10.3390/vaccines13040379
发表日期2025-05-07
摘要

摘要

Background: Pandemic influenza may cause substantial morbidity and mortality, especially in older adults and those with immunosuppressive conditions. Methods: In this phase 3, stratified, randomized, controlled, observer-blind, multicenter trial, we evaluated the safety, tolerability, and immunogenicity of an adjuvanted H5N1 vaccine (aH5N1) vs. active control (MF59-adjuvanted trivalent seasonal inactivated influenza vaccine [aTIV]) in 539 adults aged 18-60 and ≥61 years. Participants were further stratified into subgroups that were healthy (18-60 years, n = 91; ≥61 years, n = 89) or had prespecified immunosuppressive conditions (18-60 years, n = 180; ≥61 years, n = 179). Antibody responses were measured with microneutralization and single radial hemolysis (SRH) assays. Results: aH5N1 increased antibody responses in healthy persons and those with immunosuppressive conditions in both age groups, with SRH geometric mean ratios (GMRs) > 2.5 and >2.0 in participants aged 18-60 and ≥61 years, respectively, meeting former Committee for Medicinal Products for Human Use (CHMP) criteria. Responses measured with the microneutralization and SRH assays were consistent with previous studies of aH5N1. Conclusions: The aH5N1 vaccine had a clinically acceptable safety and tolerability profile with an AE profile comparable to that observed in previous aH5N1 studies. These findings support the viability of aH5N1 as a pre-pandemic influenza vaccine for the immunization of at-risk individuals when an antigenically matched pandemic influenza vaccine is not yet available.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。